News
Reversal agents curb DOAC-related bleeding but deaths still high
June 17, 2021
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
News
Are left atrial thrombi that defy preprocedure anticoagulation predictable?
June 11, 2021
Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm-control procedures.
News
First risk score to predict bleeding risk after TAVR
June 11, 2021
PREDICT-TAVR was developed and validated in two national registries in Europe and outperformed existing risk scores developed outside TAVR.
News
Single subcutaneous shot offers fast, potent platelet inhibition in STEMI
June 1, 2021
The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.
News
New AHA/ASA guideline on secondary stroke prevention
May 27, 2021
Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in an updated clinical practice guideline.
News
Update in Hospital Medicine relays important findings
May 13, 2021
Two panelists highlighted the year of research in areas most relevant and important to hospital medicine.
News
Trends in the management of pulmonary embolism
May 7, 2021
After completion of primary treatment for patients with unprovoked DVT and/or PE, guidelines suggest indefinite antithrombotic therapy over stopping anticoagulation.
News
Ruling out PE in patients with low C-PTP and D dimer of less than 1,000 ng/mL
April 30, 2021
Can we rule out pulmonary embolism (PE) in patients with a low clinical pretest probability (C-PTP) and a D dimer of less than 1,000 ng/mL?
News
FDA, CDC urge pause of J&J COVID vaccine
April 13, 2021
Treatment for traditional blood clots, such as the drug heparin, should not be used for these clots.
News
Novel antiplatelet drug: Hope for efficacy without bleeding?
April 12, 2021
A new antiplatelet drug with a completely novel mechanism of action could hold the promise of delivering the holy grail – reducing cardiac events without increasing bleeding.